Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 326.03M | 565.61M | 491.76M | 385.66M | 486.85M |
Gross Profit | 162.64M | 299.51M | 225.02M | 211.13M | 266.07M |
EBITDA | -39.07M | 18.93M | 49.90M | 86.84M | 110.30M |
Net Income | -188.78M | -36.28M | -34.65M | 16.64M | 70.13M |
Balance Sheet | |||||
Total Assets | 1.24B | 1.34B | 1.35B | 1.24B | 1.24B |
Cash, Cash Equivalents and Short-Term Investments | 21.06M | 34.85M | 128.11M | 81.70M | 312.53M |
Total Debt | 383.69M | 344.12M | 228.38M | 240.69M | 198.50M |
Total Liabilities | 869.80M | 781.52M | 737.38M | 582.39M | 583.10M |
Stockholders Equity | 369.67M | 563.52M | 614.17M | 658.17M | 659.44M |
Cash Flow | |||||
Free Cash Flow | 57.43M | -161.84M | 86.63M | -62.37M | 94.56M |
Operating Cash Flow | 133.73M | -73.33M | 110.49M | 47.77M | 153.21M |
Investing Cash Flow | -163.42M | -108.32M | -13.13M | -282.98M | -68.20M |
Financing Cash Flow | 15.99M | 88.50M | -51.77M | 20.53M | -116.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | HK$736.89M | 7.13 | 8.81% | 5.75% | 5.79% | -43.49% | |
59 Neutral | HK$15.37B | 5.76 | -7.44% | 4.08% | 11.55% | -28.15% | |
52 Neutral | HK$185.17M | ― | -7.93% | ― | 1.13% | 38.41% | |
49 Neutral | HK$279.38M | ― | -40.39% | ― | -43.73% | -434.56% | |
48 Neutral | HK$293.30M | ― | ― | ― | ― | ||
45 Neutral | HK$189.57M | ― | -26.80% | ― | -6.09% | 66.59% |
Fusen Pharmaceutical Company Limited, a pharmaceutical company incorporated in the Cayman Islands, announced that all proposed resolutions at its Annual General Meeting held on May 29, 2025, were passed unanimously by shareholders. These resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued operational stability and strategic flexibility.
Fusen Pharmaceutical Co., Ltd. has announced a significant change in its shareholding structure following the passing of Mr. Cao, the former chairman and investment manager of Fusen Trust. The Vesting Arrangement has transferred control of the voting rights of Fusen Trust Shares to Mr. Cao Zhiming, increasing his voting rights to 45.29% of the total issued shares. This change has triggered a potential requirement for a mandatory general offer under the Takeovers Code, but Mr. Cao Zhiming has obtained a waiver from this obligation.
Fusen Pharmaceutical Co., Ltd. has announced its upcoming Annual General Meeting (AGM) scheduled for May 29, 2025, in Hong Kong. The meeting will address standard business matters such as the adoption of financial statements, re-election of directors, and re-appointment of auditors. Additionally, a special resolution will be considered to authorize the company’s directors to manage share allotments and transfers, potentially impacting the company’s capital structure and shareholder value.